Anticoagulation during pregnancy
Keywords:
anticoagulation; pregnancy; prosthetic valves; heparin; warfarinAbstract
Introduction: The use of anticoagulant drugs during pregnancy has been associated with an increase in maternal and fetal morbidity and mortality.
Objective: Describe the most important considerations for the use of anticoagulant drugs during pregnancy.
Method: A bibliographic review was carried out in the PubMed/MEDLINE, Elsevier, Lilacs and SciELO databases, and the most representative references were included.
Development: The main clinical scenarios for the use of anticoagulant drugs during pregnancy are: venous thromboembolic disease, and patients with mechanical valve prostheses. There are three anticoagulation schemes during pregnancy: use of heparin, use of vitamin K antagonists and the combination of both, according to the trimester in which the pregnant woman is and the dose to be used. The use of warfarin throughout the pregnancy is the regimen that has been least associated with the risk of prosthetic thrombosis but produces fetal malformations when used in the first trimester; This risk is considerably reduced when low doses are used that keep patients in the therapeutic range. Heparins are safe for the fetus but have been associated with a higher risk of prosthetic thrombosis than warfarin. Unfractionated heparin is the drug of choice for the term of pregnancy.
Conclusions: No anticoagulation scheme is completely safe for the mother and the fetus during pregnancy. The combined scheme is the one that comes closest to a balance between maternal and fetal benefit.
Downloads
References
1.Guimarães T, Magalhães A, Veiga A, et al. Cardiopatia e gravidez, o estado da arte. Rev Port Cardiol. 2019;38(5):373---383. Disponible en: https://doi.org/10.1016/j.repc.2018.05.013
2. Muryán S, Malvino E. Cuidados intensivos cardiológicos en pacientes obstétricas. Vol V. 2aed. Argentina; 2020. P. 121-125. Disponible en: www.obstetriciacritica.com .
3. Regitz V, Roos J, Bauersachs J, et al. Guía ESC 2018 sobre el tratamiento de las enfermedades cardiovasculares durante el embarazo. Rev Esp Cardiol. 2019;72(2):161.e1-e65. Disponible en: http://doi.org/10.1016/j.recesp.2018.12.004
4. Samuel Avila W, Giunco Alexandre R, de Castro M, et al. Posicionamento da Sociedade Brasileira de Cardiologia para Gravidez e Planejamento Familiar na Mulher Portadora de Cardiopatia – 2020. Arq.Bras. Cardiol.2020; 114(5): 849-942. Disponible en: https: //doi.org/10.36660/abc.20200406
5. Sandoval Paredes J, Sandoval Paz C. Uso de fármacos durante el embarazo. Horiz Med 2018; 18(2): 71-79. Disponible en: http://dx.doi.org/10.24265/horizmed.2018.v18n2.11
6. Camacho Solís AE, Méndez Zamora AM, Martín Zamora AC. Eventos tromboembólicos y el embarazo: actualización en anticoagulación en mujeres embarazadas. Revista Médica Sinergia. 2019; 4 (5): 77 – 88. Disponible en: https://doi.org/10.31434/rms.v4i5.210
7. Muñoz Ortiz E, Velázquez Penagos J, Gándara Ricardo J, Holguín E, Peláez M, Betancourt Pizarro AM, Velázquez O. Anticoagulación en embarazada con válvula cardiaca mecánica: reto clínico para el equilibrio materno y fetal. Ginecol Obstet Mex, 2021; 89 (1): 23-50. Disponible en: https://doi.org/10.24245/gom/v89i1.4669
8. Durán-Morales MA, Ariza-Parra EJ, Colonia-Toro A. Manejo de la terapia anticoagulante durante el embarazo.MÉD.UIS.2020;33(2):65-73. Disponible en: https://doi.org/10.18273/revmed.v33n2-2020007
9.Van Hagen IM, Roos-Hesselink JW, Ruys TP, Merz WM, Goland S, Gabriel H,Lelonek M, Trojnarska O, Al Mahmeed WA, Balint HO, Ashour Z, Baumgartner H, Boersma E, Johnson MR, Hall R. Pregnancy in women with a mechanical heart
valve: Data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 2015;132:132–142. Available in: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.115.015242
10. Robert-Ebadi H, Le Gal G and Righini M. Diagnostic Management of Pregnant Women With Suspected Pulmonary Embolism. Front. Cardiovasc. Med. 2022 9:851985. doi: 10.3389/fcvm.2022.851985 Available in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967345/
11. American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018; 132: e1-e17. Available in: https://doi.org/10.1097/AOG.0000000000002706
12. Oscar Vera-Carrasco. Farmacología básica y clínica de los anticoagulantes. Cuad. - Hosp. Clín. [Internet]. 2022 Jun [citado 2022 Dic 05] ; 63( 1 ): 55-63. Disponible en: http://www.scielo.org.bo/scielo.phpscript=sci_arttext&pid=S165267762022000100009&lng=es.
13. Greer JP, Arber DA, Glader B, List AF, Means RT, Rodgers GM.
Wintrobe’s clinical hematology. 13th ed. Wolters Kluwer; 2018.
14. Breen K. Anticoagulation treatment. Medicine. 2017; 45(4): 239-243. Available in: https://doi.org/10.1016/j.mpmed.2017.01.010
15. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143:e00–e00. DOI: 10.1161/CIR.0000000000000923. Available in: https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000923
16. Lewey J, Andrade L, Levine L. Valvular Heart Disease in Pregnancy. Cardiol Clin 39 (2021) 151–161. Available in: https://doi.org/10.1016/j.ccl.2020.09.010
17. Forget AE. Challenges of Anticoagulation theraphy in pregnancy. Curr Treat Options Cardio Med. 2017; 19(10): 1-13 Available in: https://pubmed.ncbi.nlm.nih.gov/28913590/
18. Scheres LJJ, Bistervels IM, Middeldorp S. Everything the clinician needs to know about evidencebased anticoagulation in pregnancy. Blood Rev. 2019; 33: 82-97
Available in: https://doi.org/10.1016/j.blre.2018.08.001
19. Hogg K, Weitz J. Goodman y Gilman: The Pharmacological Basis of Therapeutics. 13th edition. Blood coagulation and Anticoagulant, Fibrinolytic, and Antiplatlet Drugs. New York.: McGraw-Hill; c2018: 592-593 p. Available in: https://accesspharmacy.mhmedical.com/content.aspx?sectionid=170271546&bookid=2189
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish in this journal agree to the following terms: Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0), which allows others to share the work provided that its authorship and initial publication in this journal are acknowledged. Authors may enter into separate, additional agreements for the non-exclusive distribution of the published version of the work (e.g., posting it to an institutional repository or publishing it in a book), provided that its initial publication in this journal is acknowledged. Authors are permitted and encouraged to share their work online (e.g., in institutional repositories or on their personal website) before and during the submission process, as this can lead to productive exchanges and increase citation of the published work (see The Effect of Open Access).
As the Revista Cubana de Investigaciones Biomédicas is part of the SciELO network, once articles have been accepted into the editorial process (peer review), authors may, if they agree, deposit them in SciELO Preprints and update them there once the review process and layout proofs are complete.
